Seres Therapeutics (MCRB) schedules 2026 meeting, sets proposal deadline

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

When is Seres Therapeutics (MCRB) holding its 2026 annual stockholder meeting?

What is the record date for voting at Seres Therapeutics’ 2026 annual meeting?

What is the deadline for Seres Therapeutics (MCRB) stockholder proposals for the 2026 meeting?

Why did Seres Therapeutics set a revised stockholder proposal deadline for 2026?

Where will Seres Therapeutics disclose the time and location of the 2026 annual meeting?

Which shareholders of Seres Therapeutics (MCRB) can submit proposals under Rule 14a-8?

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Seres Therapeutics, Inc. has scheduled its 2026 annual meeting of stockholders for June 9, 2026. Stockholders who hold common shares as of the close of business on April 13, 2026 will be entitled to vote at the meeting.

Because the 2026 meeting will occur more than 30 days after the 2025 meeting anniversary, the company has set a revised deadline for qualified stockholder proposals under SEC Rule 14a-8. Proposals must be received at the company’s principal executive office by the close of business on March 26, 2026 to be considered for inclusion in the 2026 proxy statement.

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

03/16/2026 - 04:42 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2026

SERES THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-37465

27-4326290

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


101 Cambridgepark Drive
Cambridge, MA		02140
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 945-9626

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common stock, par value $0.001 per share

MCRB

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

Seres Therapeutics, Inc. (the “Company”) announced today that the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”) has been scheduled for June 9, 2026. All holders of record of common stock outstanding as of the close of business on April 13, 2026 will be entitled to vote at the 2026 Annual Meeting. The time and location for the 2026 Annual Meeting will be set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting.

As the 2026 Annual Meeting is being held more than 30 days after the anniversary of the Company’s 2025 annual meeting of stockholders under Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is hereby providing notice of the below revised deadline for qualified stockholder proposals bought pursuant to Rule 14a-8 of Exchange Act.

In order for a stockholder proposal for the 2026 Annual Meeting to be eligible for inclusion in the Company’s proxy statement pursuant to Rule 14a-8 of the Exchange Act, the Company must receive the proposal and supporting statements at its principal executive office no later than the close of business on March 26, 2026 (which is the tenth (10th) day following the date of this Current Report on Form 8-K).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Seres Therapeutics will hold its 2026 annual meeting of stockholders on June 9, 2026. This is when shareholders of record can vote on company matters, including director elections and other proposals presented in the definitive proxy statement.

The record date is April 13, 2026. Only holders of Seres Therapeutics common stock outstanding at the close of business on that date will be entitled to receive notice of, and vote at, the 2026 annual meeting of stockholders.

Stockholder proposals under SEC Rule 14a-8 must be received by March 26, 2026. Proposals and supporting statements must arrive at Seres Therapeutics’ principal executive office by the close of business to be eligible for inclusion in the 2026 proxy statement.

The 2026 annual meeting will occur more than 30 days after the anniversary of the 2025 meeting. Under SEC Rule 14a-5(f), this timing change requires Seres Therapeutics to provide public notice of a revised deadline for qualified stockholder proposals.

The specific time and location of the 2026 annual meeting will be provided in Seres Therapeutics’ definitive proxy statement. That document will outline meeting logistics, agenda items, and detailed information on matters subject to stockholder vote.

Qualified stockholders who meet SEC Rule 14a-8 ownership and holding period requirements may submit proposals. To be considered for the 2026 meeting proxy, those proposals must reach Seres Therapeutics’ principal executive office by March 26, 2026.

SERES THERAPEUTICS, INC.

Date: March 16, 2026

/s/ Thomas J. DesRosier

Thomas J. DesRosier

Executive Vice President and Chief Legal Officer

3 documents